A factual term of reference for this opinion would be most helpful. Perhaps a comparison with the Lovaza launch. Personally I am not from the play station generation and do not require such instant gratification. I trust Amarin's management who are seasoned pros and have done this before-most of them with the launch of Lovaza.
They have probably forgotten more than we all know on the do's and dont's of a drug launch!
By October/November we should have a very clear trend and path forward for this company.
In the meantime if I were a short I would beware the black swan event...BO/data from statin combo product/NCE/co-promotion/up tick of RXs..etc,etc.
I can't really see the risk/reward for a short at these levels and with these trading risks but each to their own I guess.
News 
Market Data 
Discover 
AI
